Johnson & Johnson (NYSE:JNJ) might seem like the dud of the Dividend Aristocrats so far this year, with the stock down about 7% and fourth-quarter sales giving investors a little pause. But if you dig a little deeper into its business and Q4 report, you’ll find that JNJ is actually a diamond in the rough. JNJ disappointed some investors after it reported that Q4 sales were down 0.6% year-over-year. But Johnson & Johnson did beat the consensus estimate for earnings per share by 1 cent, and profits overall were up 2.5% from the year-ago period.
Before you write JNJ stock off as dead money, consider these three reasons why you should stick with Johnson & Johnson in 2015. 1. JNJ Sales Were Better Than You Think: Although sales for Johnson & Johnson’s Hepatitis C drug Olysio were down, CEO Alex Gorksy expected this to happen. 2. Of Course, There’s the Dividend: JNJ is a Dividend Aristocrat that has increased its payout every year for 52 years, including its most recent increase of 6% to 70 cents quarterly. 3. Promising New Investment: JNJ is making strategic investments that will only make Johnson & Johnson stronger. 4. Johnson & Johnson Reasonably Priced: JNJ currently has a price-to-earnings ratio under 18, making it an undervalued stock compared to its competitors.
Source: InvestorPlace
Related Articles:
- The Perfect Dividend Stock
- Bonds Look Morbid When Compared To These Dividend Stocks
- My 5 Largest Dividend Stock Positions Have Double-Digit Lifetime Returns
- The Best Dividend Stocks In The World
- 12 Dividend Stocks With 50+ Years of Consecutive Increases
________________________________________________________________
Subscribe to:
Post Comments (Atom)
Popular Posts Last 30 Days
-
Stocks that offer big dividend yields are often backed by businesses that are going through rough patches and experiencing significant downt...
-
With the calendar turning over to 2019, many of the trends causing the rise in volatility aren’t stopping. To that end, making a calculated ...
-
Many dividend stocks tumbled over the past year, since conservative investors often shift from high-yielding stocks to bonds when interest r...
-
Because we're expected to live longer than those just a generation or two removed from us, we'll need income during our retirement f...
-
This company has become an income machine for investors over the past three decades, thanks in large part to the 132 consecutive dividends i...
-
For the most part, stock market investors love the technology sector. While tech stocks were hit particularly hard during the latest market ...
-
If you want to find good deals this holiday season, forget the department stores. Instead, go to the stock market. Due to the lackluster per...
-
Showing resilience during a tough week was a group of stocks that has not been heard from much in the past two years. A group that has been ...
-
Even though GDP is growing nicely, consumer spending is red hot and unemployment is low, the stocks that are outperforming are all ones we’d...
-
The yield is 9.07%, with 1.14X coverage in Q3 '18. EVA has a $7.4B backlog that's contracted through 2025. Management expects EBITDA...
0 comments
Post a Comment
Post a Comment